Marinomed licenses cold portfolio in China
This article was originally published in Scrip
Executive Summary
Austrian biotech company Marinomed Biotechnologie has licensed Chinese rights to five of its marketed antiviral products to an undisclosed "major international pharmaceuticals company headquartered in Europe", it has said.